Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 16,842 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Available No phase listed Expanded access

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

NCT04566393
View directory record Official record
Conditions
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
Interventions
Ulixertinib (BVD-523)
Drug
Lead sponsor
xCures
Industry
Eligibility
12 Years and older
U.S. locations
26
States / cities
Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 3:05 PM EDT
Terminated No phase listed Observational

Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

NCT04057001
View directory record Official record
Conditions
Liver Transplant; Complications, Hepatitis C
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 23, 2026, 3:05 PM EDT
Withdrawn Phase 2 Interventional

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

NCT03150836
View directory record Official record
Conditions
Bladder Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Terence Friedlander, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 23, 2026, 3:05 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland

NCT05470309
View directory record Official record
Conditions
Cervical Cancer
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
30 Years to 65 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 23, 2026, 3:05 PM EDT
Terminated Phase 3 Interventional Results available

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

NCT03642132
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 23, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

NCT00243009
View directory record Official record
Conditions
Kidney Cancer
Interventions
cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 23, 2026, 3:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Integrated Population (I-POP) Health Trial

NCT04761016
View directory record Official record
Conditions
Diabetes, Hypertension, Chronic Kidney Diseases, Obesity, Chronic Disease
Interventions
Usual Care, I-POP + CHW navigation
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 3:05 PM EDT
Withdrawn Phase 2 Interventional

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

NCT03035630
View directory record Official record
Conditions
Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions
Avelumab, Sunitinib
Drug
Lead sponsor
Guru Sonpavde
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 23, 2026, 3:05 PM EDT
Completed Not applicable Interventional

Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool

NCT06533111
View directory record Official record
Conditions
Post-operative Complications
Interventions
Epic Health Record semi-structured handoff cognitive aid, Usual care
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 105 Years
Enrollment
3,763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 3:05 PM EDT
Completed No phase listed Observational

68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer

NCT03857087
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 23, 2026, 3:05 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

NCT05946798
View directory record Official record
Conditions
Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
Interventions
Acetylcholine, Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 3:05 PM EDT
Recruiting No phase listed Observational

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
Jelmyto (mitomycin) for pyelocalyceal solution
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 3:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Growth Hormone Resistance of Beta-cells A

NCT06571487
View directory record Official record
Conditions
Gestational Diabetes, Obesity, Healthy
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 3:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study to Evaluate a Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions

NCT00212446
View directory record Official record
Conditions
Preterm Birth
Interventions
Electrical Intervention (EI)
Device
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 23, 2026, 3:05 PM EDT
Completed Not applicable Interventional

A Pilot Study Comparing Telehealth and In-Person Therapy Service Delivery Following NICU Discharge

NCT06893003
View directory record Official record
Conditions
Prematurity Complications, NICU Infants, Early Intervention, Telehealth
Interventions
Baby Bridge
Other
Lead sponsor
University of Southern California
Other
Eligibility
Up to 6 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 23, 2026, 3:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comprehensive Outcomes for After Cancer Health

NCT05349227
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Interventions
Digital Health Coaching Program, Fitbit
Behavioral · Device
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 23, 2026, 3:05 PM EDT
Recruiting Phase 2 Interventional

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

NCT06493370
View directory record Official record
Conditions
Bladder Cancer
Interventions
Intravenous ascorbic acid/vitamin C
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Iowa City, Iowa • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 23, 2026, 3:05 PM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population

NCT05981183
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Transcutaneous electrical nerve stimulation unit (TENS)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 3:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Total Intravenous Versus Inhalational Anesthesia- A Geriatric Anesthesia Study

NCT06036095
View directory record Official record
Conditions
Neurocognitive Disorders, Anesthesia, Post-operative Delirium, Post-operative Cognitive Dysfunction
Interventions
Sevoflurane, Propofol
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
70 Years to 110 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 23, 2026, 3:05 PM EDT
Recruiting Not applicable Interventional

Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery

NCT02316275
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
No post-operative activity restrictions, Standard post-operative activity restriction
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 3:05 PM EDT
Completed Phase 3 Interventional

Fenretinide in Treating Patients With Cervical Neoplasia

NCT00003075
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Fenretinide, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 23, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 23, 2026, 3:05 PM EDT
Active, not recruiting Not applicable Interventional

Clinical Study of External Electrical Stimulation for Male Incontinence

NCT06620419
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Perineal-applied electrical stimulation
Device
Lead sponsor
Elidah, Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroe, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 3:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

NCT03835819
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Pembrolizumab, IMGN853
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 23, 2026, 3:05 PM EDT